Behavioral Health EBITDA Multiples 2026

ABA therapy multiples: 8x–12x EBITDA

Applied behavior analysis practices for autism treatment are the highest-valued sub-sector in behavioral health, and they have been for five years. PE capital flooded ABA starting in 2019, and even with some multiple compression from the 2022–2023 rate environment, strong ABA practices still command **8x–12x EBITDA**.

What drives the high end of the range: 90%+ commercial payer mix, at least 10 credentialed Board Certified Behavior Analysts (BCBAs) on staff (not contractors — W2), documented waitlist of 50+ patients, multi-site operations, and a management team that can run without the founder.

What puts you at the low end: heavy Medicaid dependence (some states reimburse ABA at rates that barely cover costs), high BCBA turnover, single-site operation, and any founder-clinician who generates more than 20% of revenue personally.

ABA EBITDA margins typically run **18%–28%** for well-run operations. The limiting factor is BCBA compensation — starting salaries for credentialed BCBAs hit $75K–$95K in most metros in 2025, and signing bonuses of $10K–$20K are common. Practices that try to run lean on clinical staff end up with high turnover, census gaps, and deteriorating payer relationships.

For buyers considering ABA, the acquisition guide at behavioral health practice acquisition covers the clinical staffing and payer contracting issues in detail.

• Premium range (8x–12x): commercial mix 80%+, W2 BCBAs, 50+ patient waitlist
• Discount triggers: Medicaid-heavy, high BCBA turnover, founder-dependent revenue
• Target EBITDA margin: 18%–28%
• BCBA compensation benchmark: $75K–$95K base + benefits

SUD residential multiples: 6x–9x EBITDA

Substance use disorder residential facilities — residential treatment centers (RTCs), halfway houses with clinical programs, and detox facilities — trade at **6x–9x EBITDA** in 2026.

The premium drivers are straightforward: licensed residential beds are scarce in most states, per-diem reimbursement from commercial payers runs $400–$1,200 per day for residential treatment, and the regulatory barriers to entry are high enough that new supply is slow to emerge.

Payer mix is everything in SUD residential. A facility with 70%+ commercial payer mix at $800 per diem is printing cash. The same facility at 70% Medicaid/indigent is marginally viable. State Medicaid SUD rates have been rising since the Substance Abuse Prevention and Treatment Block Grant was expanded, but they still average $150–$350 per diem — less than half of commercial rates in most markets.

JCAHO or CARF accreditation adds **0.5x–1.0x** to the multiple for SUD residential, because it is often a contractual requirement for commercial payer contracting. A non-accredited SUD facility cannot access the commercial payer rates that drive the premium.

SUD residential EBITDA margins run **22%–35%** for well-run programs at 80%+ occupancy. The key variable is census management — a 20-bed facility that runs at 75% occupancy instead of 90% loses $300K–$500K of EBITDA per year depending on rates. Buyers should model occupancy risk carefully in any SUD residential acquisition.

For SBA financing considerations specific to this modality, see SBA financing for behavioral health acquisitions.

• Premium drivers: commercial payer mix, JCAHO/CARF accreditation, licensed beds
• Occupancy benchmark: 80%+ to hit target margins
• EBITDA margin range: 22%–35%
• Per-diem range: $400–$1,200 commercial, $150–$350 Medicaid

IOP and PHP multiples: 5x–9x EBITDA

Intensive outpatient programs (IOP) and partial hospitalization programs (PHP) occupy the middle of the behavioral health multiple spectrum at **5x–9x EBITDA**. These programs treat patients who need more than weekly outpatient therapy but do not require residential care — typically 9–20 hours of clinical programming per week.

The value premium over standard outpatient comes from higher reimbursement intensity. A commercial payer might reimburse $150 per individual therapy session in outpatient, but IOP reimbursement runs $400–$900 per day for the same patient in an intensive program. This revenue-per-patient advantage creates better margins and more predictable cash flow.

IOP/PHP practices with dual-diagnosis capability (co-occurring mental health and substance use disorder) command the high end of the range. Dual-diagnosis is the most clinically complex and highest-reimbursed IOP segment.

Margin benchmarks for IOP/PHP: **20%–30% EBITDA margin** for programs running at efficient census levels. The key cost drivers are licensed clinical staff (psychiatrists for PHP programs add significant overhead), facility costs (more space required than standard outpatient), and billing complexity (IOP/PHP coding is scrutinized heavily by payers — budget for dedicated billing staff).

Buyers should pay close attention to payer contract terms for IOP/PHP. Many commercial contracts include annual rate renegotiation clauses, and payers have been tightening IOP authorization criteria since 2023. A practice that gets 80% of its IOP authorizations approved today may face a different authorization environment in 18 months.

• IOP reimbursement: $400–$900 per day commercial
• Dual-diagnosis premium: adds 0.5x–1.5x to multiple
• Target EBITDA margin: 20%–30%
• Authorization risk: verify payer approval rates by program type

Outpatient therapy multiples: 4x–7x EBITDA

Standard outpatient behavioral health — individual therapy, group therapy, psychiatric medication management — trades at **4x–7x EBITDA**. This is the most accessible entry point for first-time acquirers and the most abundant deal supply in the market.

A well-run outpatient practice with $300K–$600K EBITDA, 60%+ commercial payer mix, a diverse therapist roster of 6–10 clinicians, and a clean compliance history will trade at **5.5x–7x**. Strip out one or two of those attributes and the multiple drops to 4x–5x.

The biggest discount factor in outpatient is **therapist concentration**. Any practice where a single therapist generates more than 25% of revenue is valued at a steep discount. Buyers underwrite therapist departure risk with dollar precision: if one clinician leaves and takes their caseload, what happens to EBITDA? If the answer is "it drops 30%," that risk gets priced into the multiple.

Outpatient EBITDA margins run **15%–22%** for most practices. The margin ceiling is lower than ABA or SUD residential because revenue per patient hour is lower and therapist compensation is the primary cost.

Telehealth has been mixed for outpatient valuations. Practices that retained telehealth as a primary modality post-2022 have lower overhead (smaller physical footprint) but also lower in-network retention rates in some payer contracts that require minimum in-person visit frequency.

For a full buyer's guide to acquiring outpatient practices, see buying a behavioral health practice in 2026 and the mental health practice acquisition guide.

• Premium (5.5x–7x): commercial mix 60%+, 6+ clinicians, no concentration risk
• Discount triggers: single-clinician revenue concentration, Medicaid-heavy
• EBITDA margin: 15%–22%
• Telehealth: verify payer contract in-person minimums

Payer mix impact: the math behind the multiple

Here is the practical math on payer mix and how it moves multiples.

Take a 10-therapist outpatient practice generating $1.5M in revenue. At 70% commercial mix, average session rate is $175, and EBITDA might be $330K — a 22% margin. At 70% Medicaid mix, average session rate drops to $90, revenue on the same volume of sessions is $770K, and EBITDA might be $100K — a 13% margin.

Same physical practice, same therapists, same patient volume. The commercial-mix version produces $230K more EBITDA and trades at a higher multiple. At 6x EBITDA, that's a $1.38M price difference — roughly the cost of the entire Medicaid-mix practice.

This is why sophisticated buyers obsess over payer mix during LOI diligence. Request a payer mix analysis showing the trailing 24 months of collections by payer. Look for: - Commercial mix trend (flat, growing, or eroding) - Any single payer above 30% of collections - Medicaid rate changes in the trailing 12 months - Medicare behavioral health billing (rates have improved but are still below commercial)

Telehealth parity is the wildcard. In states with behavioral health telehealth parity laws — New York, California, Texas, Illinois — commercial payers must reimburse telehealth at the same rate as in-person visits. In states without parity, telehealth reimbursement can be 15–30% lower. A practice with 40% telehealth revenue in a non-parity state is earning less per session than a comparable in-person practice, and buyers should adjust their EBITDA multiple accordingly.

Telehealth premium: when it adds value and when it doesn't

Telehealth is a premium in some contexts and a liability in others. The distinction comes down to three variables: state parity law, payer contract terms, and patient retention.

A behavioral health practice in New York that built a robust telehealth platform during 2020–2022 and retained 40% of patients on telehealth permanently has a lower cost structure (smaller office footprint, less administrative overhead for scheduling) and access to patients across the state rather than just within driving distance of the clinic. This is a premium — buyers value the geographic diversification and the margin benefit.

Conversely, a practice in a non-parity state that shifted to telehealth and is now billing $120 telehealth sessions instead of $160 in-person sessions has compressed its own margins. Buyers will notice and discount the multiple.

Payer contract terms matter too. Some commercial contracts include in-person visit minimums — a patient must have one in-person visit per quarter to maintain in-network status. If a practice has a high telehealth volume and is not meeting those minimums, there is a potential recoupment risk during payer audits.

Ask the seller directly: have you received any payer correspondence about in-person visit ratios? Has any payer initiated a utilization review on telehealth billing in the past 24 months? Honest answers to these questions will tell you whether the telehealth revenue is durable or at risk.

• Parity states: telehealth revenue is equivalent to in-person — no discount
• Non-parity states: telehealth rates 15–30% lower — adjust EBITDA
• In-person minimums: verify payer contract compliance
• Utilization review risk: ask directly about payer correspondence